PTPN11 and neuroblastoma: Therefore, in general while RAS and RAF mutant NB have some sensitivity to trametinib, they are resistant to SHP099 (we refer to these cancers in this study as “type 1” NB) and a large subset of NB outside of this small genetic subset demonstrates sensitivity to SHP2 inhibition.